Moderna's Promising Two-in-One Flu and COVID-19 Vaccine: Higher Immune Responses in Late-Stage Trials

Cambridge, Massachusetts United States of America
Combination vaccines could offer more convenient options for people who don't like getting multiple shots.
Moderna's combination vaccine elicited higher immune responses against three influenza virus strains (H1N1, H3N2, and B/Victoria) and against SARS-CoV-2 in both age groups: those between 50 and 64 years old and those above 65.
Moderna's experimental two-in-one vaccine, mRNA-1083, shows higher immune responses to flu and COVID-19 in older adults compared to separate vaccines.
The combination shot could offer a new option for boosting uptake of updated coronavirus vaccines and reduce the burden on health systems.
The earliest the combined vaccine could hit the market is fall 2025, pending regulatory approval.
Moderna's Promising Two-in-One Flu and COVID-19 Vaccine: Higher Immune Responses in Late-Stage Trials

An experimental two-in-one vaccine, developed by Moderna, has shown promising results in an advanced clinical trial for both protecting against the flu and COVID-19. The combination shot, called mRNA-1083, produced higher immune responses to three subtypes of flu and SARS-CoV-2 in older adults compared to separate vaccines.

The ongoing trial includes adults ages 50 and older. Moderna announced the results on June 10, stating that the combined vaccine could offer a new option for boosting uptake of updated coronavirus vaccines and reduce the burden on health systems. The earliest the combined vaccine could hit the market is fall 2025, pending regulatory approval.

Moderna's combination COVID-19 and flu shot has shown positive results in a late-stage trial involving about 4,000 adults each in two age cohorts: those between 50 and 64 years old and those above 65. In both groups, the combination vaccine elicited higher immune responses against three influenza virus strains (H1N1, H3N2, and B/Victoria) and against SARS-CoV-2.

Combination vaccines could offer more convenient options for people who don't like getting multiple shots. Moderna is the only company with a positive Phase 3 flu and COVID combination vaccine. The company will engage with regulators on next steps for its combination vaccine, aiming to have it ready as early as 2025.

Moderna's competitors, Pfizer-BioNTech and Novavax, are also working on a combination shot. Pfizer-BioNTech said it was preparing a Phase 3 trial after getting positive topline results in earlier studies. Novavax's COVID and seasonal influenza vaccine is in the Phase 2 trial stage.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

No Doubts Found At Time Of Publication

Sources

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

What to know about Moderna’s combined covid-flu vaccine on the horizon

The Fixing Site: A Summary of the Article. Fenit Nirappil Monday, 10 June 2024 19:40
  • Unique Points
    • Moderna’s combined coronavirus-influenza shot produced higher immune response in older adults than separate vaccines.
    • Earliest the combined vaccine could hit the market is fall 2025, pending regulatory approval.
  • Accuracy
    • Modernas combined coronavirus-influenza shot produced higher immune response in older adults than separate vaccines.
    • Moderna is trialling a two-in-one flu and Covid-19 vaccine
    • Modernas combination COVID-19 and flu vaccine showed positive results in a late-stage trial.
    • mRNA-1083 elicited higher immune responses against three influenza virus strains and SARS-CoV-2 in both age cohorts.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

2-in-1 shot for flu and COVID shows promise in advanced trial

FibarOttaeli News Site Nicoletta Lanese Monday, 10 June 2024 21:21
  • Unique Points
    • An experimental two-in-one vaccine triggered strong immune responses against both the flu and SARS-CoV-2 in an advanced clinical trial that included adults ages 50 and older.
    • Moderna’s combined coronavirus-influenza shot produced higher immune response in older adults than separate vaccines.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna combi flu and Covid jab gives better protection, study finds

theguardian.com Article URL: https://www.theguardian.com/world/2024/feb/13/ pakistan-·coalition-·agrees-to-form-government Tobi Thomas Monday, 10 June 2024 14:14
  • Unique Points
    • Moderna is trialling a two-in-one flu and Covid-19 vaccine
    • The clinical trial showed higher immune responses to both diseases with the combined vaccine
    • New jab may be better at protecting against flu and Covid-19 than current vaccines
    • Results came from a phase 3 trial involving 8,000 participants aged 50 to 64 and those aged 65 and over
    • Moderna hopes to make the vaccine widely available as early as next year
  • Accuracy
    • The new jab may be better at protecting against flu and Covid-19 than current vaccines
    • Combination vaccines have the potential to reduce burden on health systems and offer more convenient vaccination options
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    No formal fallacies found. However, there is an example of a dichotomous depiction and an appeal to authority. The dichotomous depiction is presented in the statement 'Initial results have shown it may be better at protecting against them than what is now being used.' This implies that either the new combined vaccine is significantly better or not, without considering other possibilities. The appeal to authority can be seen in the quote from Stéphane Bancel: 'Combination vaccines have the potential to... provide stronger protection from seasonal illnesses.' These statements are not inherently fallacious, but they do lack nuance and could mislead readers.
    • Initial results have shown it may be better at protecting against them than what is now being used.
    • Stéphane Bancel: Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna says its combination COVID and flu vaccine tested better than separate shots

CBS News Site: https://www.cbsnews.com/articles/about-us/ Neal Riley Tuesday, 11 June 2024 02:47
  • Unique Points
    • Moderna’s combination COVID-19 and flu vaccine showed positive results in a late-stage trial.
    • mRNA-1083 elicited higher immune responses against three influenza virus strains and SARS-CoV-2 in both age cohorts.
    • Combination vaccines could reduce the burden on health systems and offer more convenient options.
  • Accuracy
    • Moderna's combination COVID-19 and flu vaccine showed positive results in a late-stage trial.
    • The combination vaccine produced higher immune responses in older adults than separate shots.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication